Pancreatic Disorders News

Samsung Bioepis has joined with Takeda to develop multiple novel biologic therapies, including the collaboration’s first therapeutic candidate, TAK-671 for severe acute pancreatitis, according to a press release.

Oral tablets containing purified tetrahydrocannabinol, or THC, failed to improve chronic abdominal pain better than placebo in a phase 2 randomized controlled trial.

A new trial has been launched to help researchers better understand the link between new-onset diabetes and pancreatic cancer.

Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy using the Cellvizio platform was effective for optical biopsy of pancreatic cysts, supporting its use as an imaging biomarker in pancreatic cyst diagnosis, according to new research.

The Perlmutter Cancer Center at NYU Langone Medical Center has launched their new Pancreatic Cancer Center, a multidisciplinary center to improve the diagnosis, treatment and prevention of pancreatic cancer, according to a press release.

A new biomarker panel accurately detected early stages of pancreatic ductal adenocarcinoma in human blood samples, according to new research.

Laparoscopic total pancreatectomy with islet autotransplantation and intraoperative islet separation, a new minimally invasive surgical approach for treating chronic pancreatitis, was successfully completed and improved outcomes in the first 20 patients to undergo the procedure.

A combination of two biomarker tests differentiates benign serous cystic neoplasms from potentially malignant pancreatic lesions with “near perfect” accuracy, allowing patients who test positive to avoid additional screening and surgery, according to new research.

Familial chylomicronemia syndrome (FCS) is a rare and potentially life-threatening genetic disease. The clinical hallmark of FCS is pancreatitis associated with marked chylomicronemia and triglyceridemia. It is important that gastroenterologists recognize the signs and symptoms to properly evaluate, as well as manage, patients with FCS. In this activity, a gastroenterologist will review the diagnosis, assessment, management, ongoing challenges, and future therapeutic options for patients with FCS.

The FDA has issued fast-track designation to CM4620, a calcium release-activated calcium channel inhibitor for the treatment of acute pancreatitis, for which there are currently no approved therapies, the manufacturer announced.